A global leader in Afib and pain management, the company targets a $10B+ market by 2030 through innovation, clinical trials, and expanding reimbursement. Strong financial growth is projected, with 2026 revenue guidance of $602M–$610M and positive net income.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.